ストックスクリーナーアプリを入手
14.26
1.38%
-0.20
プレマーケット:
14.04
-0.22
-1.54%
Ars Pharmaceuticals Inc (SPRY) 最新ニュース
(SPRY) Investment Analysis - news.stocktradersdaily.com
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - The Manila Times
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
ALK Abello inks neffy co-promotion deal in USA - The Pharma Letter
ARS Pharmaceuticals Partners with ALK for Neffy Promotion By Investing.com - Investing.com Nigeria
ARS Pharmaceuticals Partners with ALK for Neffy Promotion - Investing.com Australia
ARS Pharmaceuticals Signs Co-Promotion Deal With ALK-Abello for Neffy Nasal Spray in US - marketscreener.com
ARS Pharma in pact with ALK-Abelló to co-promote neffy - Seeking Alpha
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner And Global Allergy Leader Alk-Abello A/S - marketscreener.com
ALK-Abello (AKBLF) Partners with ARS Pharma for Needle-Free Alle - GuruFocus
ALK enters into neffy® co-promotion agreement in the USA - The Manila Times
ARS Pharmaceuticals and ALK-Abelló A/S Expand Co-Promotion Agreement for neffy® Nasal Spray Ahead of Back-to-School Season - Nasdaq
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians - GlobeNewswire
ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ... - Eagle-Tribune
ARS Pharma Partners With ALK to Expand neffy Nasal Spray to 9,000 US Pediatricians | SPRY Stock News - Stock Titan
REG-ALK enters into neffy® co-promotion agreement in the USA - TradingView
ARS Pharmaceuticals Has A Blockbuster Candidate (NASDAQ:SPRY) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
(SPRY) On The My Stocks Page - news.stocktradersdaily.com
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock By Investing.com - Investing.com India
ARS Pharmaceuticals director Laura Shawver sells $615,074 in stock - Investing.com Australia
US High Growth Tech Stocks To Watch Now - Yahoo Finance
ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money - Insider Monkey
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
10 Unstoppable Stocks That Could Double Your Money - Insider Monkey
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Raymond James maintains Strong Buy on SPRY stock, $32 target - Investing.com
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
neffy From ARS Pharmaceuticals, Inc - Pharmacy Times
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN
Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus
ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha
Raymond James maintains $28 target on ARS Pharma stock - Investing.com India
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):